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Abstract
Background: Molecular characterisation of normal karyotype acute myeloid leukemia (NK-AML)
allows prognostic stratification and potentially can alter treatment choices and pathways.
Approximately 45–60% of patients with NK-AML carry NPM1 gene mutations and are associated
with a favourable clinical outcome when FLT3-internal tandem duplications (ITD) are absent. High
resolution melting (HRM) is a novel screening method that enables rapid identification of mutation
positive DNA samples.
Results:  We developed HRM assays to detect NPM1  mutations and FLT3-ITD and tested
diagnostic samples from 44 NK-AML patients. Eight were NPM1 mutation positive only, 4 were
both NPM1 mutation and FLT3-ITD positive and 4 were FLT3-ITD positive only. A novel point
mutation Y572C (c.1715A>G) in exon 14 of FLT3 was also detected. In the group with de novo NK-
AML, 40% (12/29) were NPM1 mutation positive whereas NPM1 mutations were observed in 20%
(3/15) of secondary NK-AML cases. Sequencing was performed and demonstrated 100%
concordance with the HRM results.
Conclusion: HRM is a rapid and efficient method of screening NK-AML samples for both novel
and known NPM1 and FLT3 mutations. NPM1 mutations can be observed in both primary and
secondary NK-AML cases.
Background
Acute myeloid leukemia with a normal karyotype (NK-
AML) is considered to have an intermediate prognostic
risk with 5 year disease free survival (DFS) ranging
between 24–42% [1,2]. However, there is marked varia-
bility in outcome suggesting significant biological and
molecular heterogeneity within this group of AML [3].
In 2005, Falini et al. described a set of common mutations
within the final exon of the NPM1 gene in primary NK-
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AML patients, which alter the N-terminal domain nuclear
localisation signal leading to abnormal cytoplasmic accu-
mulation of the NPM1 phosphoprotein [4]. While the
precise functional effect of the NPM1 mutation is incom-
pletely understood, several groups confirmed that NK-
AML patients have a high incidence of NPM1 exon 12
mutations (~24% – 60%) [5-9]. Mutations in NPM1 are
the most frequent genetic change known in patients with
NK-AML and a number of studies have shown that NPM1
mutation positive patients have a better prognosis with
longer event-free and overall survival (OS) [10].
Schnittger et al. demonstrated that the favourable prog-
nostic implications of NPM1 mutation status are overrid-
den in FLT3-ITD positive cases which have a uniformly
poor prognosis [7]. These findings demonstrate the need
to screen patients for mutations in FLT3-ITD alongside
NPM1 [10]. However, such a molecular screening pro-
gram can be demanding on the resources of a diagnostic
laboratory. Therefore, in this study we assessed the use of
high resolution melting (HRM) analysis as a rapid
method to screen NK-AML patient samples for the critical
molecular changes in NPM1 and FLT3.
Results and Discussion
In this study, we developed HRM assays allowing rapid
assessment of the mutation status of NPM1 and the pres-
ence of the FLT3-ITD in the same run. In HRM, the PCR
product is subjected to melting in the presence of a dye
that only fluoresces when bound to double stranded DNA
[11]. As melting is sequence dependent, monitoring the
precise melting behaviour by observing the change in flu-
orescence allows the detection of variant sequences. In
addition, sequence variants in the DNA such as mutations
give rise to heteroduplexes that form earlier melting prod-
ucts allowing ready detection of mutations even at com-
paratively low concentrations.
Samples from 44 patients with NK-AML were analysed.
The median age of the patients was 62 years (range 18–89
years) and 27 (61%) patients were male. Twenty nine
(66%) had de novo AML and 15 (34%) had secondary
AML. Sixteen patients generated an abnormal melting
Figure 1
Detection of NPM1 mutations and FLT3-ITD using high resolution melting analysis. (A) The melt curve of NPM1 
exon 12 and (B) The difference plot of NPM1 exon 12. Six patient samples are shown in comparison to five normal controls. 
Four patients (#6, #12, #14 and #38) are NPM1 mutation positive and two patients (#33 and #43) are NPM1 mutation nega-
tive. (C) The melt curve of FLT3 exon 14 and (D) The difference plot of FLT3 exon 14 - Six patient samples are shown in com-
parison to five normal controls. Three patients (#6, #33 and #43) are FLT3-ITD positive and three patients (#12, #14 and #48) 
are FLT3-ITD negative. (E) The melt curve of FLT3 exon 14 and (F) The difference plot of FLT3 exon 14 - Eight patient samples 
are shown in comparison to five normal controls. One patient (#19) is positive for FLT3 Y572C and seven patients (#4, #5, 
#10, #24, #25, #26 and #30) are FLT3 mutation negative. All samples are shown in duplicate.
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profile in one of the two tested amplicons, 8 were NPM1
mutation positive only, 4 were NPM1 positive and FLT3-
ITD positive and 4 were FLT3-ITD positive only (Figure
1.).
Sequencing confirmed all the HRM detected mutations
and did not reveal any further mutations, indicating that
HRM was capable of detecting mutations with 100% sen-
sitivity in this cohort.
Table 1: Patient demographics and list of NPM1 and FLT3-ITD mutations detected
# Age Sex* FAB Prior Disease† HRM – NPM1‡ Seq – NPM1§ HRM – FLT3-
ITD
Seq-FLT3-ITD|
1 64 M M1 Nil Normal Neg Normal Neg
2 63 M M6 MDS Normal Neg Normal Neg
3 36 M M2 Nil Normal Neg Normal Neg
4 69 M basophilic leukemia RAEB-T Normal Neg Normal Neg
5 68 M M2 Nil Normal Neg Normal Neg
6 81 M M5 Nil Aberrant 860_863dupTCTG Aberrant 1754_1798dup
7 19 M M2 Nil Normal Neg Normal Neg
8 68 M M6 Nil Normal Neg Normal Neg
9 72 M M4 CMML Normal Neg Normal Neg
10 58 F M2 Nil Aberrant 860_863dupTCTG Normal Neg
11 66 F M4/5 MDS transformed Aberrant 860_863dupTCTG Normal Neg
12 51 F M4 Nil Aberrant 860_863dupTCTG Normal Neg
13 42 F M2 MDS/pelvic chloroma Normal Neg Normal Neg
14 53 M M4 Nil Aberrant 860_863dupTCTG Normal Neg
15 59 F M1 Nil Aberrant 860_863dupTCTG Aberrant 1811_1837dup 
1838_1867ins
16 69 M M1 Nil Normal Neg Normal Neg
17 52 M M1 MDS Normal Neg Normal Neg
18 74 M M1 Nil Normal Neg Normal Neg
19 66 M M0 ca prostate Aberrant 860_863dupTCTG Aberrant 1715A>G
20 52 M M1 MDS Normal Neg Normal Neg
21 75 M M1 MDS Normal Neg Normal Neg
22 56 M M0 NHL on TX Normal Neg Normal Neg
23 18 F M1 Nil Normal Neg Normal Neg
24 73 M M4 Nil Normal Neg Normal Neg
25 56 F M1 therapy related Normal Neg Normal Neg
26 53 F M4 Nil Aberrant 860_863dupTCTG Normal Neg
27 64 M M0 MDS Normal Neg Normal Neg
28 63 F M5a Nil Aberrant 861_864insCTGC Normal Neg
29 71 F M5b MDS transformed Aberrant 860_863dupTCTG Aberrant 1754_1789dup
30 89 F M6 Nil Normal Neg Normal Neg
31 28 F M4 Nil Normal Neg Normal Neg
32 69 F basophilic leukemia Nil Normal Neg Normal Neg
33 36 F M5b Nil Normal Neg Aberrant 1783_1812dup
34 54 M M1 Nil Normal Neg Normal Neg
35 52 M M1 Nil Normal Neg Normal Neg
36 82 M M4 Nil Normal Neg Aberrant 1786G>C 1787_1818dup
37 68 M M5b CMML Normal Neg Normal Neg
38 61 F M4 Nil Aberrant 860_863dupTCTG Normal Neg
39 49 M M4 Nil Normal Neg Aberrant ins ? bp ¶|
40 83 F M1 Nil Aberrant 860_863dupTCTG Normal Neg
41 72 F M4 CMML Normal Neg Normal Neg
42 57 M M4 Nil Normal Neg Normal Neg
43 42 M M1 Nil Normal Neg Aberrant 1741_1831dup 
1832_1842ins
44 49 M M6 Nil Normal Neg Normal Neg
† MDS = myelodysplastic syndrome; RAEB-T = refractory anemia with excess of blasts in transformation; CMML = chronic myelomonocytic 
leukemia; Ca prostate = prostate cancer; NHL = Non-Hodgkin lymphoma.
‡Normal = normal melt profile, Aberrant = abnormal melt profile.
§Neg = no mutation detected in the sequence; numbering according to NPM1 reference sequence NM_002520.5
| Numbering according to FLT3 reference sequence NM_004119.2 (5'UTR not included)
¶ The size of the internal tandem duplication could not be determined due to the low levels of mutant peaks in the sequence,Journal of Hematology & Oncology 2008, 1:10 http://www.jhoonline.org/content/1/1/10
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All the NPM1 mutations detected involved one of two 4
base insertions that altered the tryptophan at amino acid
position 288 and the FLT3-ITD ranged from 33–102 bases
(Table 1). These mutations were similar to those previ-
ously described [4,12,13]. All 12 NPM1 mutation positive
patients were also positive by immunohistochemistry
(IHC) on bone marrow trephine sections, showing typical
cytoplasmic localisation (data not shown).
The incidence of NPM1 mutations in the de novo AML
cases was 40% (12/29), consistent with the incidence
reported in previous studies [5-9]. Interestingly, 3/15 of
the secondary AML cases were NPM1 mutation positive
which contrasts with an earlier study, where cytoplasmic
localisation of NPM indicative of NPM1 mutations was
not seen in 135 secondary AML samples by IHC [4].
A novel point mutation Y572C in exon 14 of FLT3 was
also detected. This tyrosine residue within the juxtamem-
brane domain of FLT3 has been shown to be phosphor-
ylated in vivo [14] and could be included in the newly
described class of FLT3  juxtamembrane domain point
mutations for which the similar mutation Y591C has
been reported [15]. This illustrates the power of HRM to
detect novel as well known mutations. The use of HRM to
screen for FLT3-ITD has been previously reported [16].
HRM is rapidly becoming the most important mutation
scanning methodology. It is an in-tube method, meaning
that PCR amplification and subsequent analysis are
sequentially performed in the one tube or well. This
makes it more convenient than other scanning methodol-
ogies such as denaturing high-performance liquid chro-
matography [17]. We used a real-time PCR machine with
HRM capability rather than a stand-alone HRM instru-
ment. This facilitates quality control as the success of the
amplification can be assessed on the same platform as the
melting analysis.
HRM has no real disadvantages in mutation scanning
except that extra care needs to be taken in designing PCR
reactions to avoid primer dimers and non-specific ampli-
fication. Secondly, DNA needs to be prepared in a uni-
form fashion to avoid variation in salt concentration that
will affect the melting. In addition, the exact nature of any
mutation cannot be determined without sequencing.
Nevertheless, performing HRM as an initial screen for
potential mutations significantly reduces the volume of
samples requiring sequencing with consequent reduction
of cost and labour, and improvements to turn around
time.
Conclusion
HRM is likely to play a major role in clinical applications
as it enables rapid detection of defined and novel molec-
ular changes in clinical samples. In this study, the condi-
tions have been optimised to enable screening of normal
karyotype AML patients for both NPM1 and FLT3-ITD in
the same run. This has enhanced patient prognostication
and clinical decision making regarding therapeutic
approaches. The assays are suitable both for individual
patient diagnosis and for large scale clinical trials.
Methods
Patients and samples
DNA was extracted from archival bone marrow smears
from 44 NK-AML patients from 1999–2007 sent to the
Pathology Department of The Peter MacCallum Cancer
Centre. Normal peripheral blood samples were obtained
from 11 healthy volunteers. All samples were collected
and were obtained in accordance with the Peter MacCal-
lum Cancer Centre Ethics of Human Research guidelines.
DNA was extracted from bone marrow smears using a
standard phenol/chloroform extraction technique. DNA
was extracted from peripheral blood using the Wizard
Genomic DNA Purification Kit (Promega, Madison, WI).
High resolution melting analysis
The PCR and melting analysis for NPM1 and FLT3 muta-
tions were all performed on the LightCycler 480 (Roche
Diagnostics, Penzberg, Germany) a real-time PCR
machine with HRM capability and a 96/384 well capacity.
All samples were tested in duplicate. At least 5 different
normal controls for each gene were included in each run.
Approximately 10 ng of DNA was amplified in a total vol-
ume of 10 μL containing 400 nM each of the relevant for-
ward and reverse primer (NPMex12F-
TGATGTCTATGAAGTGTTGTGGTTCC, NPMex12R-
CTCTGC ATTATAAAAAGGACAGCCAG; or FLT3ex14F-
TGCAGAACTGCCTATT CCTAACTGA; FLT3ex14R-TTC-
CATAAGCTGTTGCGTTCATCAC, 4 mM (NPM1) or 3 mM
(FLT3) MgCl2, and LightCycler 480 High-Resolution
Melting Master (Roche Diagnostics). The cycling condi-
tions were the same for both amplicons allowing them to
be performed in the one run. The conditions were 95°C
(10 min) and a touch down of 10 cycles of 95°C (10 sec),
65°C–55°C (10 sec, 1°C/step), 72°C (30 sec) and a fur-
ther 45 cycles. The melting program was 95°C (1 min)
45°C (1 min), then 65°C–95°C (5 sec, 1°C/sec). Thirty
acquisitions were collected per °C. Upon completion of
the run (approximately 2 hours), analysis was performed
using the software supplied with the LightCycler 480. The
melting curves were normalised and temperature shifted
to allow samples to be directly compared. Difference plots
were generated by selecting a negative control as the base-
line and the fluorescence of all other samples was plotted
relative to this sample. Significant differences in fluores-
cence were indicative of mutations.Publish with BioMed Central    and   every 
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Sequencing
Sequencing was performed on all samples. Approximately
10 ng of DNA was amplified in a total volume of 25 μL
containing 200 nM each of M13 tagged primers, 2 mM
MgCl2, 200 μM each dNTPs, 0.5 units FastStart Taq
(Roche Diagnostics) and 1× Buffer. The primers used were
the same as stated above except that the M13 sequences 5'
TGTAAAACGACGGCCAGT and 5' CAGGAAACAGCTAT-
GACC were tagged to the forward and reverse primers
respectively. The cycling conditions were 95°C (10 min)
and 45 cycles of 94°C (30 sec), 64°C (30 sec), 72°C (30
sec) and 72°C for 10 min. The products were checked on
a 2% ethidium bromide stained agarose gel before
sequencing.
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Note added in proof
After this manuscript was submitted, another report of
NPM1 mutations in secondary AML has appeared [18].
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